In Vitro Susceptibilities of Vitreous Candida Endophthalmitis Isolates to Newer and Traditional Antifungal Agents.
To investigate in vitro microbiological susceptibilities of Candida vitreous endophthalmitis isolates using traditional and newer antifungal agents. The current study is a retrospective, consecutive case series of 17 vitreous culture-proven Candida endophthalmitis isolates from 2011 to 2017 from Bascom Palmer Eye Institute. Susceptibilities to echinocandins, triazoles, polyenes, and nucleoside analogs were obtained. The study isolates consisted of 59% C. albicans, 17% C. glabrata, 12% C. tropicalis, and 12% C. parapsilosis. Isolates demonstrated 100% sensitivity to all antifungals tested except anidulafungin (85% sensitive) and fluconazole (88.2% sensitive). Comparing in-class agents, minimum inhibitory concentration (MIC) values for voriconazole were lower than other triazoles, whereas micafungin had lower MIC values compared with other echinocandins. Both traditional and newer antifungals included agents that were highly efficacious against in vitro Candida species. Although the authors' study data suggest that older, established antifungals are likely adequate for the treatment of Candida endophthalmitis, newer antifungal agents also can be considered. [Ophthalmic Surg Lasers Imaging Retina. 2019;50:S13-S17.].